Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Halozyme Therapeutics (NASDAQ:HALO) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02, Zacks reports. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%.

Halozyme Therapeutics Trading Down 0.7 %

Halozyme Therapeutics stock traded down $0.39 during mid-day trading on Tuesday, hitting $57.90. 1,656,112 shares of the company’s stock were exchanged, compared to its average volume of 1,276,348. The company’s 50 day simple moving average is $52.69 and its 200-day simple moving average is $54.51. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $7.37 billion, a P/E ratio of 19.17, a PEG ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics has a fifty-two week low of $35.50 and a fifty-two week high of $65.53.

Wall Street Analyst Weigh In

HALO has been the topic of several research analyst reports. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.